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Background: iPrevent is an online breast cancer (BC) risk management decision support tool. It uses an internal switching
algorithm, based on a woman’s risk factor data, to estimate her absolute BC risk using either the International Breast Cancer
Intervention Study (IBIS) version 7.02, or Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm
version 3 models, and then provides tailored risk management information. This study assessed the accuracy of the 10-year
risk estimates using prospective data.
Methods: iPrevent-assigned 10-year invasive BC risk was calculated for 15 732 women aged 20–70 years and without BC at re-
cruitment to the Prospective Family Study Cohort. Calibration, the ratio of the expected (E) number of BCs to the observed (O)
number and discriminatory accuracy were assessed.
Results: During the 10 years of follow-up, 619 women (3.9%) developed BC compared with 702 expected (E/O¼1.13; 95% confi-
dence interval [CI] ¼1.05 to 1.23). For women younger than 50 years, 50 years and older, and BRCA1/2-mutation carriers and
noncarriers, E/O was 1.04 (95% CI ¼ 0.93 to 1.16), 1.24 (95% CI ¼ 1.11 to 1.39), 1.13 (95% CI ¼ 0.96 to 1.34), and 1.13 (95% CI ¼ 1.04
to 1.24), respectively. The C-statistic was 0.70 (95% CI¼0.68 to 0.73) overall and 0.74 (95% CI ¼ 0.71 to 0.77), 0.63 (95% CI ¼ 0.59
to 0.66), 0.59 (95% CI ¼ 0.53 to 0.64), and 0.65 (95% CI ¼ 0.63 to 0.68), respectively, for the subgroups above. Applying the newer
IBIS version 8.0b in the iPrevent switching algorithm improved calibration overall (E/O¼1.06, 95% CI ¼ 0.98 to 1.15) and in all
subgroups, without changing discriminatory accuracy.
Conclusions: For 10-year BC risk, iPrevent had good discriminatory accuracy overall and was well calibrated for women aged
younger than 50 years. Calibration may be improved in the future by incorporating IBIS version 8.0b.
Clinical decision support tools can help integrate and person-
alize evidence to assist clinicians and patients to make better-
informed decisions (1). Tools that are computerized,
personalized, and accessible not only to clinicians but also to
patients themselves have better uptake and result in greater
adherence to recommended practice (2). iPrevent is a new,
evidence-based, personalized breast cancer (BC) risk assess-
ment and risk management decision support tool (3) developed
to assess risk across the entire risk spectrum. It is freely avail-
able online at https://www.petermac.org/iprevent. It is designed
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for collaborative use between women and their clinicians and
was developed to be consistent with best practice in risk com-
munication. iPrevent assesses a woman’s personal BC risk and
provides tailored risk management advice, including informa-
tion about chemoprevention, risk-reducing surgeries, lifestyle
modification, and screening (Figure 1) (4).
There are many available BC-risk prediction models, but
their use in the clinic can be hampered by a lack of clear guide-
lines on which models should be applied in which circumstan-
ces. iPrevent chooses from two commonly used pedigree-based
models, according to the algorithm shown in Figure 2—the
Breast and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm (BOADICEA) version 3 (v3) (5) or the
International Breast Cancer Intervention Study (IBIS) model
version 7.02 (v7.02) (6)—to estimate each woman’s 10-year and
lifetime BC risk based on her risk factors. Both BOADICEA and
IBIS, which we have recently shown (7) are well calibrated and
outperform other commonly used risk models like Gail (8) and
BRCAPRO (9), are applicable to all women across the spectrum
of absolute familial risk. In addition, IBIS incorporates nonfami-
lial risk factors and is appropriate for women without a BC fam-
ily history. Other commonly used BC models such as the Gail (8)
or Breast Cancer Surveillance Consortium model (10) have been
developed and validated only for women at average risk.
After providing a personal BC risk estimate, iPrevent gives a
menu of appropriate potential risk management interventions
based on Australian National Guidelines (11,12), applying pub-
lished relative risk reductions for relevant interventions (eg,
33% relative risk reduction for 5 years of tamoxifen use) (13) to
give personalized, detailed, quantitative information on how
the intervention changes a woman’s absolute BC risk. Women
and their doctors can choose to see this information presented
as statistics, pictograms, and/or graphs. Individualized lifestyle
advice is also provided, based on the risk factor data the woman
supplies.
A pilot study of iPrevent use by women and their clinicians
found it had good usability and acceptability and suggested that
it might improve the accuracy of BC risk perception and en-
hance BC prevention knowledge without increasing BC worry or
anxiety (14).
The primary aim of this study was to assess the calibration
and discrimination of the 10-year BC risk estimates provided by
the current online version of iPrevent, using data from a pro-
spective cohort. During the course of this study, v8.0b of IBIS
was released, which updated model parameters for the associa-
tion between hormone replacement therapy (HRT) and BC risk
and also allowed for optional inclusion of mammographic den-
sity and single nucleotide polymorphism (SNP) data. Hence, we
also prospectively validated the iPrevent switching algorithm,
incorporating IBIS v8.0b.
Methods
This validation study was performed using data from the
Prospective Family Study Cohort (15), which pooled data from
two cohorts: the Breast Cancer Family Registry (BCFR) (16) and
the Kathleen Cuningham Foundation Consortium for Research
into Familial Breast Cancer (kConFab) Follow-Up Study (17).
These cohorts are enriched for women with an increased famil-
ial risk of BC. The BCFR and kConFab used the same risk factor
questionnaire at enrollment, which collected data on demo-
graphics, height, weight, breast and ovarian surgeries, repro-
ductive history, and lifestyle factors. The cancer family history
Figure 1. Screenshots of the Online iPrevent Breast Cancer Risk Assessment and Risk Management Decision Support Tool. A) iPrevent gathers information about life-
style and medical and family history and, using that information, provides 10-year breast cancer risk estimates as well as lifetime risk estimates (not shown). B)
iPrevent provides a menu of appropriate risk management options for each woman depending on her category of risk, based on her absolute risk estimate and Cancer
Australia guidelines. An example for a woman at moderate risk of breast cancer. C) iPrevent provides personalized estimates of the absolute reduction in breast cancer
risk that may be expected with prevention strategies such as tamoxifen.
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questions asked about breast and other cancers diagnosed in
participants and their first- and second-degree relatives, includ-
ing ages at diagnosis and age last known to be alive, for all fam-
ily members. Screening for germline BRCA1 and BRCA2
mutations by the BCFR and kConFab typically involved testing
the affected proband and/or the youngest affected woman in
each family, followed by cascade testing of other family mem-
bers for the family-specific mutation if present in the proband.
Incident BC diagnoses were verified through pathology reports
for 84% of cases. Participants provided written informed con-
sent and were followed for a median of 10 years. The cohort pro-
tocols were approved by institutional review boards at each of
the respective institutions.
At baseline, there were 18 856 women in the Prospective
Family Study Cohort without a personal history of invasive or
in situ BC (15). We excluded from the analyses those women
who had bilateral mastectomy prior to cohort entry (n¼ 113),
those with follow-up time of less than 2 months (n¼ 517),
those with prior history of ovarian cancer (n¼ 316), those
younger than 20 years or older than 70 years at baseline
(n¼ 2082), and those for whom inadequate pedigree data
were available (n¼ 96), leaving 15 732 eligible participants
from 6694 families.
We manually applied the iPrevent switching algorithm to
the entire cohort (which allowed us to consider the impact of
two versions of IBIS: 7.02 and 8.0b). We first determined for each
participant whether iPrevent would use the IBIS or BOADICEA
model to generate the iPrevent risk estimate (Figure 2). The soft-
ware packages IBIS v7.02 (http://www.ems-trials.org/riskevalua-
tor/) and BOADICEA v3 (https://pluto.srl.cam.ac.uk/cgi-bin/bd3/
v3/bd.cgi) were then used to assign 10-year BC risks. These risk
estimates were then further modified based on preventive
measures used prior to baseline by applying a 33% reduction in
relative risk for women who had taken tamoxifen for BC pre-
vention prior to baseline and a 50% reduction in relative risk for
women who had had a bilateral oophorectomy before age
45 years (although the validity of the latter has recently been
questioned [18], and this may need future modification). The
same process was subsequently undertaken using IBIS v8.0b,
but mammographic density and SNP-based polygenic risk
(which can be entered in IBIS v8.0b but not v7.2) were not avail-
able for this dataset (19).
Figure 2. iPrevent software algorithm for breast cancer risk estimation. Based on their personal and/or first- or second-degree family history of cancer and BRCA1/
BRCA2-mutation status, the iPrevent 10-year breast cancer risk estimate was derived from the IBIS model for 9749 participants and the BOADICEA model for the
remaining 5983 participants. # IBIS- or BOADICEA-derived risk estimates were further modified to obtain the iPrevent risk estimate by applying a 33% relative risk re-
duction for women who had taken tamoxifen for breast cancer prevention prior to baseline and a 50% relative risk reduction for women who had had a bilateral oopho-
rectomy before age 45 years. AH ¼ atypical hyperplasia; BOADICEA ¼ Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; BRCA
mutation ¼ BRCA1 or BRCA2 pathogenic germline mutation; IBIS ¼ International Breast Cancer Intervention Study; LCIS ¼ lobular carcinoma in situ.
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Statistical Analysis
The calibration and discriminatory accuracy of the 10-year
iPrevent BC risk estimates were assessed for the overall cohort
and also for subgroups 1) younger than 50 years at baseline, 2)
50 years or older at baseline, 3) BRCA1- and BRCA2- mutation
carriers (combined), and 4) noncarriers. Follow-up time was
censored at date of in situ BC diagnosis, bilateral mastectomy,
death, loss to follow-up, or on reaching 10 years. If follow-up
time was less than 10 years, we used the method described by
Amir and colleagues (20) to adjust the predicted risk to the
available follow-up time.
For calibration, the expected number of invasive BC cases
based on the iPrevent-assigned risk (E) was compared with the
observed number of cases (O) (21). The 95% confidence intervals
(CI) for the ratio of expected to observed numbers (E/O) was cal-
culated by E/O*EXP(61.96*SQRT[1/O]) (22). For the overall sam-
ple and in the younger than age 50 years, 50 years and older,
and noncarrier subgroups, the mean iPrevent-assigned risk to
observed BC incidence was calculated overall and for each dec-
ile of risk, with separate deciles used for BRCA1- and BRCA2-mu-
tation carriers. To compare calibration between IBIS v7.02 and
v8.0b, we calculated the estimated calibration index (ECI) de-
fined as the average squared difference between observed and
predicted risk. Values of ECI closer to zero indicate better cali-
bration (23).
To evaluate discriminatory accuracy, the receiver operating
characteristic curves for the development of invasive BC within
10 years, overall, and for the subgroups defined above were plot-
ted and the C-statistic computed. A C-statistic of 0.6–0.7 is con-
sidered “sufficient,” 0.7–0.8 is considered “good,” and 0.8–0.9
“very good” (21). The calibration and discrimination analyses
were conducted using the RMAP 0.03–01 (https://gailg.github.io/
rmap/) algorithm in the R environment and Stata version 14
(Stata Corporation, College Station, TX). All other analyses were
conducted using SAS version 9.4.
Results
Of the 15 732 eligible women, 619 (3.9%) were diagnosed with in-
vasive BC and 415 (2.6%) died without a BC diagnosis during the
10 years of follow-up. An additional 6078 were alive and without
invasive BC with less than 10 years’ follow-up (and were cen-
sored at date of last follow-up), leaving 8620 women unaffected
with invasive BC at 10 years. Table 1 shows the distribution of
risk factors for each outcome group. Most women (62.3%) were
younger than 50 years at baseline. There were 584 BRCA1-muta-
tion carriers (3.7%) and 491 BRCA2-mutation carriers (3.1%) iden-
tified in the study sample. Of the total sample, 21% reported use
of HRT.
The calibration results are summarized in Table 2. The
iPrevent-assigned number of expected incident BCs was 702
compared with 619 observed (E/O¼ 1.13, 95% CI ¼ 1.05 to 1.23).
For women younger than 50 years at baseline, there were 343
expected cases of BC and 330 observed (E/O¼ 1.04, 95% CI ¼ 0.93
to 1.16). For women 50 years and older at baseline, there were
359 expected cases of BC and 289 observed (E/O¼ 1.24, 95% CI ¼
1.11 to 1.39). For BRCA1- or BRCA2-mutation carriers, there were
155 expected cases of BC compared with 137 observed (E/
O¼ 1.13, 95% CI ¼ 0.96 to 1.34) and for noncarriers, 547 expected
and 482 observed (E/O¼ 1.13, 95% CI ¼ 1.04 to 1.24). A sensitivity
analysis excluding 407 women who had taken tamoxifen or
been on a chemoprevention trial prior to their BC diagnosis did
not appreciably change these results (data not shown).
Figure 3A shows that, for the overall cohort, iPrevent was
well calibrated overall except for those in the highest decile of
risk, where iPrevent overpredicted risk (mean 10-year iPrevent-
expected risk of 19.1% compared with a mean observed risk of
14.7%). There were similar findings for all subgroups except for
women younger than 50 years at baseline, where calibration
was good across the spectrum of risk (Figure 3, C, E, G, and I), in-
cluding the highest-risk decile.
When the analyses were repeated using the same switching
algorithm for iPrevent (Figure 2) but with IBIS v8.0b instead of
IBIS v7.02, the calibration improved overall (E/O¼ 1.06, 95% CI ¼
0.98 to 1.15; Table 2) and for noncarriers and both age sub-
groups, but particularly for women 50 years and older (lower
ECIs; Table 2). Calibration for BRCA1- and BRCA2-mutation car-
riers was unchanged because the iPrevent switching algorithm
is constrained to choose BOADICEA as the risk estimation
model for mutation carriers (Table 2 and Figure 3 B, D, F, H, and
J). Regarding discriminatory accuracy, the C-statistic for the en-
tire sample was 0.70 (95% CI ¼ 0.68 to 0.73), 0.74 (95% CI ¼ 0.71 to
0.77) for women younger than 50 years at baseline, 0.63 (95% CI
¼ 0.59 to 0.66) for those 50 years and older at baseline, and 0.59
(95% CI ¼ 0.53 to 0.64) for BRCA1- and BRCA2-mutation carriers
(combined) and 0.65 (95% CI ¼ 0.63 to 0.68) for noncarriers
(Figure 4 and Table 2). The discriminatory accuracy did not
change appreciably when analyses were repeated using the
same switching algorithm for iPrevent (Figure 2), but incorporat-
ing IBIS v8.0b instead of IBIS v7.02 (Table 2).
Discussion
Accurate estimation of a woman’s personal BC risk facilitates
the use of evidence-based management strategies appropriate
for her risk level and allows calculation of the absolute risk-
reduction benefit from preventive interventions.
In this validation study, based on 10-year BC risk estimates,
iPrevent was well calibrated for women younger than 50 years
at baseline. This is an important group of women, for whom
other relatively user-friendly risk estimation tools, such as the
Gail model, do not perform well (8). The calibration of iPrevent
for women 50 years or older and for BRCA1- and BRCA2-muta-
tion carriers was generally good, except for those in the top dec-
ile of risk, where it tended to be overestimated. Specifically,
iPrevent tended to overestimate risk for women 50 years and
older with an assigned 10-year risk no less than 14.3% and for
BRCA1- and BRCA2-mutation carriers with an assigned 10-year
risk no less than 35.7%. The overestimation of risk found in this
study for the highest-risk decile is consistent with our previous
study, using the same sample, which found similar findings for
the IBIS and BOADICEA models when used separately (7).
Uptake of chemoprevention after baseline does not appear to
explain the overestimation of risk; in our sensitivity analyses
that excluded women who took chemoprevention medications
prior to their first BC, the overall inferences were the same.
Similarly, we do not believe the overestimation is explained by
uptake of bilateral oophorectomy after baseline because we
have recently shown that premenopausal bilateral oophorec-
tomy did not reduce BC risk in this cohort (18). We also censored
women at bilateral mastectomy. Regardless, the extent of over-
estimation is unlikely to be of clinical importance because the
actual 10-year BC risks for these women substantially exceed
thresholds for intensified screening and medical prevention
(and for mutation carriers, risk-reducing mastectomy).
4 of 9 | JNCI Cancer Spectrum, 2019, Vol. 3, No. 4
Table 1. Distribution of risk factors by breast cancer outcome
Risk factors
Unaffected after 10 y
(n¼ 8620)
No. (%)
Follow-up <10 y
(n¼ 6078)
No. (%)
Died within 10 y
(n¼415)
No. (%)
Breast cancer within 10 y
(n¼ 619)
No. (%)
All
(n¼ 15 732)
No. (%) P
Age at interview, y <.001
20–29 1197 (13.9) 1053 (17.3) 5 (1.2) 34 (5.5) 2289 (14.5)
30–39 2004 (23.2) 1383 (22.8) 24 (5.8) 119 (19.2) 3530 (22.4)
40–49 2239 (26.0) 1508 (24.8) 55 (13.3) 177 (28.6) 3979 (25.3)
50–59 1877 (21.8) 1292 (21.3) 117 (28.2) 162 (26.2) 3448 (21.9)
60–70 1303 (15.1) 842 (13.9) 214 (51.6) 127 (20.5) 2486 (15.8)
Race/ethnicity <.001
Non-Hispanic white 7390 (85.7) 4281 (70.4) 318 (76.6) 522 (84.3) 12 511 (79.5)
Non-Hispanic black 236 (2.7) 448 (7.4) 38 (9.2) 16 (2.6) 738 (4.7)
Hispanic 309 (3.6) 905 (14.9) 34 (8.2) 38 (6.1) 1286 (8.2)
Asian 336 (3.9) 223 (3.7) 9 (2.2) 26 (4.2) 594 (3.8)
Other 251 (2.9) 163 (2.7) 11 (2.7) 11 (1.8) 436 (2.8)
Unknown 98 (1.1) 58 (1.0) 5 (1.2) 6 (1.0) 167 (1.1)
Age at menarche, y <.01
11 1466 (17.0) 1091 (17.9) 83 (20.0) 91 (14.7) 2731 (17.4)
12–13 4543 (52.7) 3069 (50.5) 188 (45.3) 331 (53.5) 8131 (51.7)
 14 2530 (29.4) 1823 (30.0) 140 (33.7) 190 (30.7) 4683 (29.8)
Unknown 81 (0.9) 95 (1.6) 4 (1.0) 7 (1.1) 187 (1.2)
BMI, kg/m2 <.001
< 25 4830 (56.0) 2924 (48.1) 174 (41.9) 309 (49.9) 8237 (52.4)
25–<30 2213 (25.7) 1617 (26.6) 125 (30.1) 177 (28.6) 4132 (26.3)
 30 1402 (16.3) 1413 (23.2) 103 (24.8) 128 (20.7) 3046 (19.4)
Unknown 175 (2.0) 124 (2.0) 13 (3.1) 5 (0.8) 317 (2.0)
Age at first live birth, y <.001
< 20 993 (11.5) 913 (15.0) 96 (23.1) 71 (11.5) 2073 (13.2)
20–24 2520 (29.2) 1675 (27.6) 167 (40.2) 206 (33.3) 4568 (29.0)
25–29 1953 (22.7) 1188 (19.5) 64 (15.4) 121 (19.5) 3326 (21.1)
 30 922 (10.7) 642 (10.6) 29 (7.0) 94 (15.2) 1687 (10.7)
Nulliparous 2232 (25.9) 1660 (27.3) 59 (14.2) 127 (20.5) 4078 (25.9)
Hormones taken for menopause <.001
Ever 1930 (22.4) 1137 (18.7) 169 (40.7) 161 (26.0) 3397 (21.6)
Never 6438 (74.7) 4827 (79.4) 235 (56.6) 436 (70.4) 11 936 (75.9)
Unknown 252 (2.9) 114 (1.9) 11 (2.7) 22 (3.6) 399 (2.5)
Menopausal status <.001
Pre- 4946 (57.4) 3730 (61.4) 66 (15.9) 298 (48.1) 9040 (57.5)
Post- 2855 (33.1) 1998 (32.9) 326 (78.6) 268 (43.3) 5447 (34.6)
Unknown 819 (9.5) 350 (5.8) 23 (5.5) 53 (8.6) 1245 (7.9)
Age at menopause (among postmenopausal), y <.001
<40 334 (11.7) 259 (13.0) 41 (12.6) 37 (13.8) 671 (12.3)
40–49 935 (32.7) 671 (33.6) 102 (31.3) 84 (31.3) 1792 (32.9)
50 1027 (36.0) 704 (35.2) 119 (36.5) 111 (41.4) 1961 (36.0)
Unknown 559 (19.6) 364 (18.2) 64 (19.6) 36 (13.4) 1023 (18.8)
Benign breast disease <.001
Yes 2353 (27.3) 1623 (26.7) 105 (25.3) 219 (35.4) 4300 (27.3)
No 5972 (69.3) 4330 (71.2) 302 (72.8) 377 (60.9) 10 981 (69.8)
Unknown 295 (3.4) 125 (2.1) 8 (1.9) 23 (3.7) 451 (2.9)
BRCA1/2 mutation <.0001
BRCA1 carrier 184 (2.1) 301 (5.0) 17 (4.1) 82 (13.2) 584 (3.7)
BRCA2 carrier 129 (1.5) 294 (4.8) 13 (3.1) 55 (8.9) 491 (3.1)
Noncarrier* 8307 (96.4) 5483 (90.2) 385 (92.8) 482 (77.9) 14 657 (93.2)
Number of first-degree relatives with breast cancer <.001†
0 1477 (17.1) 1157 (19.0) 88 (21.2) 83 (13.4) 2805 (17.8)
1 5633 (65.3) 3878 (63.8) 232 (55.9) 347 (56.1) 10 090 (64.1)
2 1510 (17.5) 1043 (17.2) 95 (22.9) 189 (30.5) 2837 (18.0)
Number of second-degree relatives with breast cancer <.001†
0 4173 (48.4) 2678 (44.1) 203 (48.9) 240 (38.8) 7294 (46.4)
1 2858 (33.2) 2042 (33.6) 139 (33.5) 227 (36.7) 5266 (33.5)
2 1589 (18.4) 1358 (22.3) 73 (17.6) 152 (24.6) 3172 (20.2)
Number of third-degree relatives with breast cancer <.001†
0 5794 (67.2) 3701 (60.9) 291 (70.1) 386 (62.4) 10 172 (64.7)
1 1673 (19.4) 1227 (20.2) 57 (13.7) 127 (20.5) 3084 (19.6)
2 1153 (13.4) 1150 (18.9) 67 (16.1) 106 (17.1) 2476 (15.7)
*Noncarriers are defined as women not known to be BRCA1- or BRCA2-mutation carriers, so they include tested and untested women. BMI ¼ body mass index.
†P value was also <.001 after adjusting for age at baseline.
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Therefore, the overestimation would be unlikely to lead to an
inappropriate change in their clinical management.
Importantly, when we used the iPrevent switching algorithm
with IBIS v8.0b (rather than v7.02), iPrevent was well calibrated
overall for all subgroups. Given that mammographic density
and SNP data were not available for this validation study, the
improved calibration, seen predominantly for women 50 years
and older, suggests that the improved performance might be
explained at least in part by the different treatment of HRT
model parameters between the two versions of IBIS. HRT use
has declined dramatically since the 2002 release of the
Women’s Health Initiative findings (24), and the improvement
in calibration using IBIS version 8.0b rather than IBIS v7.02
might be less relevant to a contemporary sample of women
who may be less likely to use HRT (the vast majority of the base-
line data in our study were collected prior to 2002).
Nevertheless, using either version of IBIS, the iPrevent algo-
rithm provides good calibration for women younger than
50 years.
iPrevent was found to have good discriminatory accuracy (C-
statistic ¼ 0.70, 95% CI ¼ 0.68 to 0.73) overall and with C-
statistics ranging from 0.59 to 0.74 for the subgroups. The over-
all discriminatory accuracy of iPrevent compares favorably with
those found in our prior study of the Gail, BRCAPRO, BOADICEA
v3, and IBIS v8.0b risk estimation models, based on the same
sample. In that prior study, the C-statistics for the overall sam-
ple ranged between 0.60 (95% CI ¼ 0.58 to 0.62) for the Gail
model and 0.71 (95% CI ¼ 0.69 to 0.73) for the IBIS v8.0b model,
with a C-statistic of 0.70 (95% CI ¼ 0.68 to 0.72) for BOADICEA v3
(7). However, the similar C-statistics for iPrevent, IBIS, and
BOADICEA imply that the internal model-switching algorithm
programmed into iPrevent does not substantially improve the
discriminatory accuracy of the risk estimates provided by either
model alone. Nevertheless, iPrevent has the advantage of a user
interface that has been designed for use both by consumers and
clinicians, and iPrevent provides tailored risk management ad-
vice, which the other tools do not provide.
iPrevent was developed in response to qualitative research
conducted with Australian clinicians and women (25–27). They
indicated that an evidence-based, computerized tool to facili-
tate collaborative assessment and management of BC risk by
women and their health-care providers would address a major
Table 2. Calibration and discrimination of iPrevent overall and by subgroups*
Current iPrevent (BOADICEA version 3
and IBIS version 7.02)
Future iPrevent (BOADICEA version 3
and IBIS version 8.0b)
Subgroups Expected Observed
Expected/Observed
(95% CI)
C-statistic
(95% CI) ECI Expected Observed
Expected/Observed
(95% CI)
C-statistic
(95% CI) ECI
Overall 702 619 1.13 (1.05 to 1.23) 0.70 (0.68 to 0.73) 0.102 657 619 1.06 (0.98 to 1.15) 0.70 (0.68 to 0.73) 0.077
<50 y 343 330 1.04 (0.93 to 1.16) 0.74 (0.71 to 0.77) 0.076 332 330 1.01 (0.90 to 1.12) 0.74 (0.71 to 0.77) 0.062
50 y 359 289 1.24 (1.11 to 1.39) 0.63 (0.59 to 0.66) 0.179 325 289 1.13 (1.00 to 1.26) 0.63 (0.60 to 0.66) 0.117
BRCA1/2 carrier 155 137 1.13 (0.96 to 1.34) 0.59 (0.53 to 0.64) 0.982 155 137 1.13 (0.96 to 1.34) 0.59 (0.53 to 0.64) 0.982
Noncarrier 547 482 1.13 (1.04 to 1.24) 0.65 (0.63 to 0.68) 0.049 502 482 1.04 (0.95 to 1.14) 0.65 (0.63 to 0.68) 0.017
*BOADICEA ¼ Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; ECI ¼ estimated calibration index; IBIS ¼ International Breast Cancer
Intervention Study.
Figure 3. Calibration of iPrevent 10-year estimates of invasive breast cancer for women in the Prospective Family Study Cohort by quantile, overall, and for subgroups
by age and mutation carriers. Calibration of iPrevent estimated 10-year breast cancer risk by decile. The coordinates on the x-axis represent the mean 10-year expected
risks from iPrevent. The coordinates on the y-axis represent the estimates of 10-year breast cancer probabilities based on the women’s observed breast cancer status,
and the bars denote 95% confidence intervals for the observed risk. For each subgroup, calibration was assessed using BOADICEA V3 and IBIS V7.02 to emulate the cur-
rent online version of iPrevent (A, C, E, G, I) and using BOADICEA V3 and IBIS V8.0b to simulate a future updated version of iPrevent (B, D, F, H, J). BOADICEA ¼ Breast
and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; IBIS ¼ International Breast Cancer Intervention Study.
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area of need (25–27), especially if the tool could be used by
women and printed out prior to the consultation (to save time).
iPrevent currently uses Australian guidelines to determine the
risk management information that is provided to women at
each risk level, but future iterations of iPrevent could be made
country specific with modifications to align the risk manage-
ment output with local guidelines (11,12,28–30).
A recent review identified 16 published BC risk estimation
models (31), including IBIS and BOADICEA, but few of those
models couple risk management to risk estimation, and studies
have demonstrated that clinicians have difficulty applying
existing risk models in clinical practice (32). There are some on-
line risk management tools that enable users to receive infor-
mation about their risk with suggestions on how to modify it,
such as Cancer Australia’s Familial Risk Assessment–Breast and
Ovarian Cancer tool (33), the Pink Hope Know Your Risk tool
(34), and the Washington University Your Disease Risk tool
based on the Nurses’ Health Study (35). However, these models
have either not used pedigree models and therefore are not ap-
plicable across the spectrum of risk (35) and/or the underlying
risk estimation models that the tools use are not published, and
there is no information available regarding the accuracy of the
risk estimates they provide (33,34).
Strengths of this validation study include its large sample
size with comprehensive and systematically collected baseline
risk factor assessment and long follow-up (average more than
10 years), resulting in a large number of incident BCs. A limita-
tion of our study was that most participants were non-Hispanic
white. The IBIS and BOADICEA models that underpin the
iPrevent risk prediction do not account for differences in under-
lying BC incidence rates by race or ethnicity, so further valida-
tion using racially diverse cohorts is important. Another
potential limitation is that almost all women in our study had
at least some family history of BC, so further validation using a
cohort of women without a family history of the disease would
be valuable. In addition, our study sample lacked data on mam-
mographic density and SNP-based polygenic risk, which are in-
cluded in IBIS v8.0b and have been shown to enhance BC risk
prediction (36,37), thus our study may underestimate the accu-
racy of BC risk estimates that would be provided if IBIS v8.0b
were incorporated into iPrevent in the future.
A key advantage of iPrevent is that it can easily be used to
apply relative risk for preventive factors through multiplying
the absolute risks from the base models by the relative risk, as-
suming there is no interaction between the relative risk factor
and the absolute risk like we have shown for body mass index
(38). iPrevent currently does this for tamoxifen and risk-
reducing surgery, but it can easily be adapted to other risk fac-
tors that are not included in the existing risk models. iPrevent
uses IBIS v7.02, but IBIS v8.0b, which includes mammographic
density, was released in September 2017. Adding mammo-
graphic density and SNP data has been shown to make small
improvements to the performance of the IBIS model (36). The
addition of SNP data also improves BC risk stratification (37).
iPrevent uses BOADICEA v3, which does not consider the effects
of mutations in genes other than BRCA1 and BRCA2. Potential
iPrevent users are warned not to use iPrevent if they have a mu-
tation in another BC predisposition gene. BOADICEA v4 (39)
includes the effects of PALB2, CHEK2, and ATM loss-of-function
mutations. Pathogenic mutations in these genes are rare, so our
study is likely to have included few such women. BOADICEA v5
has recently been published and includes the associations with
a 313-SNP polygenic risk score, other lifestyle and hormonal risk
factors, and mammographic density (40). Future iterations of
iPrevent will consider these recent developments and could
also potentially incorporate other new risk factors such as sex
hormone levels (41) and double-strand DNA break repair pheno-
type (42).
A major advantage of iPrevent over other risk estimation tools
is that it provides personalized information on BC risk manage-
ment. Another advantage is that the decision about which BC
risk estimation model to use is automated, relieving the user of
the need for expert knowledge of the performance characteristics
of all the relevant risk estimation models. This enables use of
iPrevent by women themselves, or their primary care physicians.
Future iterations of iPrevent could include IBIS v8.0b rather than
v7.02 because, as we have demonstrated, the former improves
calibration, even when mammographic density and polygenic
risk are not available. As risk estimation models evolve and im-
prove, iPrevent can be updated to integrate the best performing
future models. Although initially designed for use in Australia, fu-
ture versions of iPrevent could be country specific, aligning risk
management information with the guidelines of the country in
which iPrevent is being used. Clinical decision support tools like
iPrevent may help achieve better precision prevention and
screening and ultimately achieve the critical goal of reducing BC
incidence and mortality.
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